Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).

Shannon L PuhallaVéronique DiérasBanu K ArunBella KaufmanHans P M W WildiersHyo S HanJean-Pierre AyoubVered StearnsYuan YuanTeresa HelstenBridget Riley-GillisErin MurphyMadan G KunduMeijing WuDavid MaagChristine K RatajczakCyril Y RamathalMichael L Friedlander

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Crossover veliparib monotherapy demonstrated limited antitumor activity in patients who experienced disease progression on placebo plus carboplatin/paclitaxel. PFI appeared to affect veliparib activity. BRCA reversion mutations may promote cross-resistance and limit veliparib activity following progression on platinum.

Keyphrases

open label
phase iii
phase ii study
double blind
placebo controlled
combination therapy
study protocol
randomized controlled trial
young adults
radiation therapy
chemotherapy induced